Search results

  1. Type 2 diabetes: dulaglutide (ESNM59)

    Summary of the evidence on dulaglutide for treating type 2 diabetes to inform local NHS planning and decision-making

  2. Digital ulcers: sildenafil (ESUOM42)

    Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making

  3. Gouty arthritis: canakinumab (ESNM23)

    Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

  4. Type 2 diabetes: lixisenatide (ESNM26)

    Summary of the evidence on lixisenatide (glucagon-like peptide-1 [GLP-1] mimetic) for treating type 2 diabetes to inform local NHS planning and decision-making

  5. Pulmonary sarcoidosis: infliximab (ES2)

    Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

  6. Type 2 diabetes: alogliptin (ESNM20)

    Summary of the evidence on alogliptin (a dipeptidyl peptidase-4 [DPP-4] inhibitor) for type 2 diabetes to inform local NHS planning and decision-making

  7. Hypersexuality: fluoxetine (ESUOM46)

    Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making